Dopaminergic challenges in social anxiety disorder: Evidence for dopamine D3 desensitisation following successful treatment with serotonergic antidepressants

Journal of Psychopharmacology

Volumn 24, Issue 5, 2010, Pages 709-716

  Hood, S D ^a,b   Potokar, J P ^b   Davies, S J C ^b   Hince, D A ^a,b   Morris, K ^b   Seddon, K M ^b   Nutt, D J ^b   Argyropoulos, S V ^b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Dopamine; Pramipexole; Social anxiety; Ssri; Sulpiride

Indexed keywords

CLONAZEPAM; DOPAMINE 3 RECEPTOR; ESCITALOPRAM; PAROXETINE; PRAMIPEXOLE; PROLACTIN; SULPIRIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOPAMINERGIC SYSTEM; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; MALE; MORNING DOSAGE; NAUSEA; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOMETRY; RECEPTOR DOWN REGULATION; REMISSION; SELF REPORT; SINGLE DRUG DOSE; SOCIAL PHOBIA; STRESS; TASK PERFORMANCE; VERBAL BEHAVIOR; VISUAL ANALOG SCALE;

ADULT; ANXIETY DISORDERS; BENZOTHIAZOLES; CROSS-OVER STUDIES; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PROLACTIN; PROTEIN ISOFORMS; QUESTIONNAIRES; RECEPTORS, DOPAMINE D3; SEROTONIN UPTAKE INHIBITORS; STRESS, PSYCHOLOGICAL; SULPIRIDE; TIME FACTORS; YOUNG ADULT;

EID: 77952215442     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881108098144     Document Type: Article

References (37)

1. Ainsworth, K., Smith, SE, Zetterstrom, TS, Pei, Q., Franklin, M., Sharp, T. (1998) Effect of antidepressant drugs on dopamine D1 and D2 receptor expression and dopamine release in the nucleus accumbens of the rat. Psychopharmacology (Berl) 140: 470-477.
2. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), fourth ed. Washington DC: APA.
3. Argyropoulos, SV, Bell, CJ, Nutt, DJ (2001) Brain function in social anxiety disorder. Psychiatr Clin North Am 24: 707-722. Argyropoulos, SV, Hood, SD, Adrover, M., Bell, CJ, Rich, AS, Nash
4. JR, et al. (2004) Tryptophan depletion reverses the therapeutic effect of selective serotonin reuptake inhibitors in social anxiety disorder. Biol Psychiatry 56: 503-509.
5. Bartoszyk, GD (1998) Anxiolytic effects of dopamine receptor ligands: I. Involvement of dopamine autoreceptors. Life Sci 62: 649-663.
6. Beck, AT, Steer, RA (1987) The Psychological Corporation. San Antonio, TX: Harcourt Brace Jovanovic.
7. Black, KJ, Hershey, T., Koller, JM, Videen, TO, Mintun, MA, Price, JL, et al. (2002) A possible substrate for dopamine-related changes in mood and behavior: prefrontal and limbic effects of a D3-preferring dopamine agonist. Proc Natl Acad Sci U S A 99: 17113-17118.
8. Bond, AJ, Lader, MH (1974) The use of analogue scales in rating subjective feelings. Br J Med Psychol 47: 211-218.
9. Bressolle, F., Bres, J., Faure-Jeantis, A. (1992) Absolute bioavailability, rate of absorption, and dose proportionality of sulpiride in humans. J Pharm Sci 81: 26-32.
10. Condren, RM, Sharifi, N., Thakore, JH (2002) A preliminary study of dopamine-mediated prolactin inhibition in generalised social phobia. Psychiatry Res 111: 87-92.
11. Connor, KM, Davidson, JR, Churchill, LE, Sherwood, A., Foa, E., Weisler, RH (2000) Psychometric properties of the Social Phobia Inventory (SPIN). New self-rating scale. Br J Psychiatry 176: 379-386.
12. Dhir, A., Kulkarni, SK (2007) Involvement of dopamine (DA)/serotonin (5-HT)/sigma (sigma) receptor modulation in mediating the antidepressant action of ropinirole hydrochloride, a D(2)/D(3) dopamine receptor agonist. Brain Res Bull 74: 58-65.
13. Fawcett, J., Clark, DC, Scheftner, WA, Gibbons, RD (1983) Assessing anhedonia in psychiatric patients. Arch Gen Psychiatry 40: 79-84.
14. Fresco, DM, Coles, ME, Heimberg, RG, Liebowitz, MR, Hami, S., Stein, MB, et al. (2001) The Liebowitz Social Anxiety Scale: a comparison of the psychometric properties of self-report and clinician-administered formats. Psychol Med 31: 1025-1035.
15. Grant, KA, Shively, CA, Nader, MA, Ehrenkaufer, RL, Line, SW, Morton, TE, et al. (1998) Effect of social status on striatal dopamine D2 receptor binding characteristics in cynomolgus monkeys assessed with positron emission tomography. Synapse 29: 80-83.
16. Guy, W. (1976) ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Washington, DC: US Department of Health, Education, and Welfare.
17. Imperato, A., Mulas, A., Di Chiara, G. (1986) Nicotine preferentially stimulates dopamine release in the limbic system of freely moving rats. Eur J Pharmacol 132: 337-338.
18. Johnson, MR, Lydiard, RB, Zealberg, JJ, Fossey, MD, Ballenger, JC (1994) Plasma and CSF HVA levels in panic patients with comorbid social phobia. Biol Psychiatry 36: 425-427.
19. Mehta, MA, Montgomery, AJ, Kitamura, Y., Grasby, PM (2008) Dopamine D2 receptor occupancy levels of acute sulpiride challenges that produce working memory and learning impairments in healthy volunteers. Psychopharmacology (Berl) 196: 157-165.
20. Mierau, J., Schneider, FJ, Ensinger, HA, Chio, CL, Lajiness, ME, Huff, RM (1995) Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. Eur J Pharmacol 290: 29-36.
21. Mikkelsen, EJ, Detlor, J., Cohen, DJ (1981) School avoidance and social phobia triggered by haloperidol in patients with Tourettegs disorder. Am J Psychiatry 138: 1572-1576.
22. Mizuki, Y., Suetsugi, M., Ushijima, I., Yamada, M. (1997) Differential effects of dopaminergic drugs on anxiety and arousal in healthy volunteers with high and low anxiety. Prog Neuropsychopharmacol Biol Psychiatry 21: 573-590.
23. Pich, EM, Samanin, R. (1986) Disinhibitory effects of buspirone and low doses of sulpiride and haloperidol in two experimental anxiety models in rats: possible role of dopamine. Psychopharmacology (Berl) 89: 125-130.
24. Piercey, MF (1998) Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinsongs disease. Clin Neuropharmacol 21: 141-151.
25. Richard, IH (2005) Anxiety disorders in Parkinsongs disease. Adv Neurol 96: 42-55.
26. Robinson, H., Hood, S. (2007) Social anxiety disorder - a review of pharmacological treatments. Curr Psychiatry Rev 3: 95-122.
27. Schneier, FR, Liebowitz, MR, Abi-Dargham, A., Zea-Ponce, Y., Lin, SH, Laruelle, M. (2000) Low dopamine D(2) receptor binding potential in social phobia. Am J Psychiatry 157: 457-459.
28. Schneier, FR, Martinez, D. bi-Dargham, A., Zea-Ponce, Y., Simpson, HB, Liebowitz, MR, et al. (2008) Striatal dopamine D(2) receptor availability in OCD with and without comorbid social anxiety disorder: preliminary findings. Depress Anxiety 25: 1-7.
29. Sheehan, DV, Lecrubier, Y., Sheehan, KH, Amorim, P., Janavs, J., Weiller, E., et al. (1998) The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59 (Suppl. 20). 22-33.
30. Sokoloff, P., Giros, B., Martres, MP, Bouthenet, ML, Schwartz, JC (1990) Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347: 146-151.
31. Spielberger, CD, Gorsuch, RL, Lushene, R., Vagg, PR, Jacobs, GA (1983) Manual for the State-Trait Anxiety Inventory. Palo Alto, CA: Consulting Psychologistsg Press.
32. Talalaenko, AN, Abramets, IA, Stakhovskii, Y., Shekhovtsov, AA, Chernikov, AV, Shevchenko, SL (1994) The role of dopaminergic mechanisms on the brain in various models of anxious states. Neurosci Behav Physiol 24: 284-288.
33. Tiihonen, J., Kuikka, J., Bergstrom, K., Lepola, U., Koponen, H., Leinonen, E. (1997) Dopamine reuptake site densities in patients with social phobia. Am J Psychiatry 154: 239-242.
34. Tillfors, M., Furmark, T., Marteinsdottir, I., Fischer, H., Pissiota, A., Langstrom, B., et al. (2001) Cerebral blood flow in subjects with social phobia during stressful speaking tasks: a PET study. Am J Psychiatry 158: 1220-1226.
35. Willner, P., Hale, AS, Argyropoulos, S. (2005) Dopaminergic mechanism of antidepressant action in depressed patients. J Affect Disord 86: 37-45.
36. Wittchen, HU, Fehm, L. (2001) Epidemiology, patterns of comorbidity, and associated disabilities of social phobia. Psychiatr Clin North Am 24: 617-641.
37. Wittchen, HU, Jacobi, F. (2005) Size and burden of mental disorders in Europe-a critical review and appraisal of 27 studies. Eur Neuropsychopharmacol 15: 357-376.